RedHill Biopharma Ltd. (RDHL) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2023
Loading P/E history...
RDHL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, RedHill Biopharma Ltd. (RDHL) trades at a price-to-earnings ratio of -0.1x, with a stock price of $1.01 and trailing twelve-month earnings per share of $-5.17.
The current P/E is 227% below its 5-year average of 0.1x. Over the past five years, RDHL's P/E has ranged from a low of 0.1x to a high of 0.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, RDHL trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, RDHL trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RDHL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RDHL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $688M | 28.1 | - | - | |
| $2B | 33.6 | 4.50Best | +1883%Best | |
| $1B | 176.0 | - | -79% | |
| $90B | 19.2Lowest | - | +49% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RDHL Historical P/E Data (2023–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $36.50 | $218.00 | 0.2x | +48% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $12.75 | $215.00 | 0.1x | -48% |
Average P/E for displayed period: 0.1x
See RDHL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RDHL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RDHL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRDHL — Frequently Asked Questions
Quick answers to the most common questions about buying RDHL stock.
Is RDHL stock overvalued or undervalued?
RDHL trades at -0.1x P/E, below its 5-year average of 0.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RDHL's valuation compare to peers?
RedHill Biopharma Ltd. P/E of -0.1x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is RDHL's PEG ratio?
RDHL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2023.